LMAM
ALXN

Legg Mason Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Legg Mason Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-3,300
Closed -$548K – 142
2014
Q3 		$548K Sell
3,300
-300
-8% -$49.3K 0.39% 109
2014
Q2 		$563K Sell
3,600
-300
-8% -$47.4K 0.36% 121
2014
Q1 		$594K Buy
+3,900
New +$620K 0.35% 127

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Legg Mason Asset Management's ALXN Position: Q4 2014 in Review

Legg Mason Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2014, closing a stake of 3,300 shares — an estimated $548K sold.

Legg Mason Asset Management first reported a position in ALXN in Q1 2014 and held it in 3 quarters. The position peaked at $594K in Q1 2014. 578 funds tracked by Wall St. Rank hold ALXN as of Q4 2014.

  • Legg Mason Asset Management reported no remaining Alexion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Legg Mason Asset Management sold 3,300 Alexion Pharmaceuticals shares in Q4 2014, an estimated $548K.
  • Legg Mason Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 3 quarters.
  • Legg Mason Asset Management's Alexion Pharmaceuticals position peaked at $594K in Q1 2014.
  • 578 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2014.

Based on Legg Mason Asset Management's 13F filing for Q4 2014, filed 17 Feb 2015.